Immix Biopharma, Inc. (Nasdaq: IMMX) recently announced a significant expansion of its clinical trial sites across the United States for the NEXICART-2 study, focusing on relapsed/refractory AL Amyloidosis. This expansion aims to provide broader patient access to innovative therapy options and
U.S. lawmakers are raising alarms about clinical trials conducted in China, specifically those affiliated with the Chinese military or located in the Xinjiang Uyghur Autonomous Region. This heightened vigilance is poised to dramatically impact how the U.S. FDA scrutinizes data from these trials.
Recent research breakthroughs have revealed an intriguing and unexpected benefit of certain cancer drugs: the potential to protect against Alzheimer's disease. Originally developed for combating cancer, these medications have shown promise in preventing Alzheimer's in animal models such
The European Commission's recent authorization of Regeneron's bispecific antibody drug Ordspono (odronextamab) for the treatment of two types of lymphoma marks a significant milestone in the European market. Garnering approval for use across 27 European Union countries, Ordspono is now
The journey from a new chemical entity (NCE) to a marketable drug product is a complex, multifaceted process that demands an intricate blend of scientific expertise and practical knowledge. The transformation involves a deep understanding of organic chemistry, analytical development, pharmaceutical
Clinical trials are the bedrock upon which medical advancements are discovered and validated. However, the traditional processes involved in clinical trials are fraught with inefficiencies, high costs, and prolonged durations that hinder timely medical innovations. Ushur, a leader in AI-powered
